奥翔药业：两款产品获得化学原料药上市申请批准通知书

Core Viewpoint - Aoxiang Pharmaceutical (603229) has received approval from the National Medical Products Administration for the marketing of its active pharmaceutical ingredients, Palbociclib and Dapagliflozin [1] Group 1 - The company announced the receipt of the approval notice for the marketing application of Palbociclib and Dapagliflozin [1]